News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Hedge Fund Wants Actelion Ltd. CEO To Quit
February 4, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - Actelion (ATLN.VX) shares rose 3.5 percent on Friday after hedge fund shareholder Elliott Advisors called for its chairman and chief executive to resign from the board in a push for a sale of the Swiss biotech firm.
Twitter
LinkedIn
Facebook
Email
Print
People
MORE ON THIS TOPIC
Layoff Tracker
Pfizer ramps up ongoing restructuring, Lisata axes 72% of staff
August 5, 2026
·
73 min read
·
BioSpace Editorial Staff
Earnings
Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts
August 5, 2026
·
3 min read
·
Tristan Manalac
Earnings
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
August 5, 2026
·
2 min read
·
Annalee Armstrong
IPO
2026 IPO stock tracker: How newly public biotechs are performing
August 5, 2026
·
1 min read
·
Gabrielle Masson
